Scynexis opened higher at $3.42, compared with its previous close of $3.42. In the last trading session, the stock traded between $3.30 and $3.59. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Scynexis is now worth
$ 7.87
Resulting in a loss of
$ 92.13 (92.13%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.10 (-2.87%)
Day High
$3.59
Day Low
$3.30
Day Open
$3.42
Prev Close
$3.42
Volume
59,395
1W Return
-14.29%
1M Return
-17.59%
3M Return
-31.54%
6M Return
-49.69%
1Y Return
-31.00%
Fundamentals
Market Cap ($ Mn)
33
PE Ratio
-
PB Ratio
0.80
PEG Ratio
-
ROE
-18.25%
ROCE
-19.56%
EPS (TTM)
$-0.85
Investment Returns
1 Week
-14.29%
1 Month
-17.59%
3 Months
-31.54%
6 Months
-49.69%
9 Months
-48.16%
Financials
Quarterly
All values in $ Mn
0.3
Sep 25
18.6
Dec 25
0.0
Mar 26
0.0
Mar 26
0.2
Jun 26
0.0
Sep 26
Updates
5Nov
Scynexis Q3FY26 Results: Net loss $8.5M, secures $214M BARDA funding
Net loss narrowed slightly to $8.5 million in Q3FY26 from $8.6 million in Q3FY25. EPS of $(0.71) beat analyst consensus estimate of $(0.72) by 1.39%. Secured up to $214 million BARDA contract for SCY-247 antifungal candidate. Cash position stands at $63.2 million as of September 30, 2026.
7 days ago
22Oct
Scynexis to present SCY-247 pipeline data at IDWeek conference
Scynexis will present SCY-247 data at IDWeek on October 23, 2026. SCY-247 shows activity against drug-resistant fungal strains. BARDA contract provides up to $214 million for development. Candidate holds Orphan Drug, QIDP, and Fast Track designations.
22 days ago
6Oct
Scynexis completes Phase 1 safety study of AMPK activator SCY-770
Scynexis completed Phase 1 study of SCY-770 in healthy adults. Drug showed favorable safety profile at higher doses. Phase 2 proof-of-concept study for ADPKD set for Q4 2026. SCY-770 targets multiple drivers of cyst growth in kidney disease.
